By all accounts, the 2020 political environment is one of the most contentious in American history. The two parties that dominate the political system, liberal and conservative, are even more entrenched in their separate ideals and doubling down during the presidential election cycle. The federal budget, immigration, and health care are the top issues discussed around the watercooler, kitchen table, and coffee shops—and of course the president’s impeachment is looming large.
ONS member Donna Clark, RN, BSN, OCN®, was a dedicated oncology nurse whose impact changed the lives of countless patients with cancer for more than 30 years. Clark passed away on February 4, 2020, after a storied career as an oncology nurse and cancer survivor. Her experiences as both patient and healthcare professional allowed her to cross the gap, relate to patients, and empathize with their cancer journey. Her focus on nursing excellence left a lasting impact on the profession and resonates throughout the larger oncology nursing community.
Although cancer biosimilars have been used in European countries and in U.S. supportive care for some time, biologic medications are still new to cancer treatment in the United States. With greater support coming in at the federal level and from agencies like the U.S. Food and Drug Administration (FDA) and Federal Trade Commission, the rising biosimilar tide could soon reach a new highwater mark for healthcare professionals—and nurses specifically.
The Woodhull Study on Nurses and the Media: Health Care’s Invisible Partner showed that nurses were quoted in only 4% of health stories in the news media. In 2018, Mason and team published the Woodhull Study Revisited: Nurses’ Representation in Health News Media 20 Years Later. They found that after two decades, only 2% of health stories in the news media quoted nurses; although not statistically significant, the decrease is still a concern.
Modest differences may exist among women with diabetes compared to healthy controls when it comes to adhering to screening recommendations for breast, cervical, and colorectal cancers, according to results of a study published in Diabetologia.
Cancer is second only to heart disease as the leading cause of death in the United States. But heart conditions overlap with cancer in more ways than mortality. Chemotherapy, immunotherapy, radiation, and the myriad medication combinations used in cancer can lead to various complications, including cardiotoxic side effects. Because of the prevalence of heart disease, many patients with cancer also present with pre-existing cardiac comorbidities.
Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).
Participation in clinician and patient conversations about lung cancer screening—as well as the actual screening itself—is relatively low. According to one study, only 3.9% of screening-
eligible patients had undergone lung cancer screening. Because the screening recommendations are newer, most patients are unaware that they exist, and research highlights that only 10%–12% of the patient population has had conversations with their clinicians about it.
The Iowa Democratic Caucus did not go as smoothly as the political prognosticators expected. Most news outlets are only reporting the level of dysfunction with a voting app that delayed the final numbers significantly, but beneath that is one truth that still rings true: Americans want solutions to their healthcare problems. Health care remained the number one policy issue for 41% of caucus attendees, an astoundingly high rate that beat every other issue handedly.
Get to know Julie Painter, MSN, RN, AOCNS®, OCN®, director-at-large on the ONS Board of Directors from 2017–2020. Julie is a clinical nurse specialist/nurse practitioner at the Community Hospital of Indianapolis in Indiana.